Regorafenib Description

Regorafenib is an orally-administered inhibitor of assorted kinases. It is used for the analysis of metastatic colorectal blight and avant-garde gastrointestinal stromal tumours.

Regorafenib is adumbrated for the analysis of patients with metastatic colorectal blight (CRC) who accept been ahead advised with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS agrarian type, an anti-EGFR therapy. Regorafenib is aswell adumbrated for the analysis of patients with locally advanced, unresectable or metastatic gastrointestinal stromal bump (GIST) who accept been ahead advised with imatinib mesylate and sunitinib malate.